CR10591A - Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol - Google Patents
Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicolInfo
- Publication number
- CR10591A CR10591A CR10591A CR10591A CR10591A CR 10591 A CR10591 A CR 10591A CR 10591 A CR10591 A CR 10591A CR 10591 A CR10591 A CR 10591A CR 10591 A CR10591 A CR 10591A
- Authority
- CR
- Costa Rica
- Prior art keywords
- production
- conjugates
- insulin
- polyethylene glycol
- growth factor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 101710186630 Insulin-1 Proteins 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un metodo para la produccion de IGG-I o variante de IGF-I PEGilado en la lisina, y dicha variante comprende uno o dos aminoacidos(s) seleccionados del grupo que consiste en lisina 27, 65 y/o 68 sustituidos independientemente por otro aminoacido polar, que se caracteriza por cultivar una celula huesped procariota que comprende un vector de expresion que contiene un acido nucleico que codifica una proteina de fusion que comprende dicho IGF-I o variante de IGF-i unido en el extremo N-terminal al extremo C-terminal de un propeptido en el que dicho propeptdio finaliza en el C-terminal con los aminoacidos-Y-Pro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06018170 | 2006-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10591A true CR10591A (es) | 2009-04-03 |
Family
ID=37667695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10591A CR10591A (es) | 2006-08-31 | 2009-01-29 | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol |
Country Status (21)
Country | Link |
---|---|
US (4) | US7625996B2 (es) |
EP (1) | EP2059261B1 (es) |
JP (1) | JP5184532B2 (es) |
KR (1) | KR101106931B1 (es) |
CN (1) | CN101511390B (es) |
AR (1) | AR062575A1 (es) |
AU (1) | AU2007291502B2 (es) |
BR (1) | BRPI0715943A2 (es) |
CA (1) | CA2662062C (es) |
CL (1) | CL2007002502A1 (es) |
CO (1) | CO6251278A2 (es) |
CR (1) | CR10591A (es) |
ES (1) | ES2397660T3 (es) |
IL (1) | IL196736A (es) |
MA (1) | MA30660B1 (es) |
MX (1) | MX2009002011A (es) |
NO (1) | NO20090451L (es) |
PE (1) | PE20080912A1 (es) |
RU (1) | RU2009106118A (es) |
TW (1) | TW200819468A (es) |
WO (1) | WO2008025528A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
CA2638823A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
WO2008025527A1 (en) | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Method for the production of insulin-like growth factor-i |
EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS BASED ON ESTERS |
AU2009231394B2 (en) * | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
EP2376520B1 (en) | 2008-12-19 | 2014-02-12 | Indiana University Research&Technology Corporation | Insulin analogs |
WO2010080607A1 (en) * | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
KR101485646B1 (ko) * | 2010-02-11 | 2015-01-22 | 에프. 호프만-라 로슈 아게 | Igf―ⅰ 폴리(에틸렌 글리콜) 컨쥬게이트 |
JP5969469B2 (ja) | 2010-06-16 | 2016-08-17 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
GB201012784D0 (en) | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
WO2013096386A1 (en) | 2011-12-20 | 2013-06-27 | Indiana University Research And Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
CA2928851A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
CN108383902A (zh) | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
RU2678134C2 (ru) | 2013-03-14 | 2019-01-23 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты инсулин-инкретин |
WO2014205617A1 (en) * | 2013-06-24 | 2014-12-31 | Shandong University | Lanthanide labeled peptide and use thereof |
BR112016005716A2 (pt) | 2013-10-02 | 2017-09-12 | Nat Institutes Of Health | miméticos de fator de crescimento semelhante à insulina para uso em terapia |
UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
EP3197912B1 (en) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Lipidated amide-based insulin prodrugs |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
EP3420087B1 (en) * | 2016-02-23 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Peptide-based methods for treating neurological injury |
EP3911668A1 (en) | 2019-01-18 | 2021-11-24 | The Regents of the University of Colorado, a body corporate | Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE220101T1 (de) | 1983-04-25 | 2002-07-15 | Chiron Corp | Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren |
IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US6235488B1 (en) | 1988-09-29 | 2001-05-22 | Agilent Technologies, Inc. | Surface preparation for chemical-specific binding |
EP0400472B1 (en) | 1989-05-27 | 1996-04-03 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
US5158875A (en) * | 1989-08-25 | 1992-10-27 | Amgen Inc. | Production of biologically active insulin-like growth factor i from high expression host cell systems |
NZ236819A (en) | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5861373A (en) | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
DK0597033T3 (da) | 1991-08-01 | 1997-06-02 | Genentech Inc | IGF-1 til forbedring af den neurale tilstand |
AU6048294A (en) | 1992-11-25 | 1994-06-22 | Amgen Boulder Inc. | Modified insulin-like growth factors |
WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
EP1017794A1 (en) | 1997-02-06 | 2000-07-12 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
US20030069177A1 (en) * | 2000-05-16 | 2003-04-10 | Genentech, Inc. | Method for treating cartilage disorders |
US20030204864A1 (en) * | 2001-02-28 | 2003-10-30 | Henry Daniell | Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids |
US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
US7067485B2 (en) | 1997-11-07 | 2006-06-27 | Chiron Corporation | IGF-I composition and its use |
US6248546B1 (en) | 1998-03-09 | 2001-06-19 | Diagnostic Systems Laboratories, Inc. | Assay of IGFBP complex |
WO1999055362A1 (en) | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Spray dried formulations of igf-i |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
IL143834A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
PT1165119E (pt) | 1999-04-08 | 2004-02-27 | Genentech Inc | Composicao baseada em polipeptidos com cargas opostas |
US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
WO2001088149A1 (fr) * | 2000-05-16 | 2001-11-22 | Center For Advanced Science And Technology Incubation, Ltd. | Polypeptides de clivage de repetitions telomeriques |
US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
EP1370282A2 (en) | 2000-10-13 | 2003-12-17 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
CA2716959A1 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
WO2002094853A2 (en) | 2001-05-21 | 2002-11-28 | Nektar Therapeutics Al, Corporation | Antibodies specific for poly(ethylene glycol) |
KR101162908B1 (ko) * | 2002-12-26 | 2012-07-06 | 마운틴 뷰 파마슈티컬즈, 인크. | 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체 |
EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
JP4988599B2 (ja) | 2005-01-07 | 2012-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Igf−1融合ポリペプチドおよびその治療的使用 |
US7612178B2 (en) * | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
AU2009231394B2 (en) | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
-
2007
- 2007-08-28 CL CL200702502A patent/CL2007002502A1/es unknown
- 2007-08-29 AU AU2007291502A patent/AU2007291502B2/en not_active Ceased
- 2007-08-29 PE PE2007001177A patent/PE20080912A1/es not_active Application Discontinuation
- 2007-08-29 ES ES07801961T patent/ES2397660T3/es active Active
- 2007-08-29 AR ARP070103823A patent/AR062575A1/es not_active Application Discontinuation
- 2007-08-29 CN CN2007800319871A patent/CN101511390B/zh not_active Expired - Fee Related
- 2007-08-29 US US11/846,857 patent/US7625996B2/en not_active Expired - Fee Related
- 2007-08-29 EP EP07801961A patent/EP2059261B1/en active Active
- 2007-08-29 JP JP2009525971A patent/JP5184532B2/ja not_active Expired - Fee Related
- 2007-08-29 WO PCT/EP2007/007540 patent/WO2008025528A1/en active Application Filing
- 2007-08-29 RU RU2009106118/10A patent/RU2009106118A/ru not_active Application Discontinuation
- 2007-08-29 MX MX2009002011A patent/MX2009002011A/es active IP Right Grant
- 2007-08-29 BR BRPI0715943-9A patent/BRPI0715943A2/pt not_active IP Right Cessation
- 2007-08-29 KR KR1020097003975A patent/KR101106931B1/ko not_active IP Right Cessation
- 2007-08-29 TW TW096132101A patent/TW200819468A/zh unknown
- 2007-08-29 CA CA2662062A patent/CA2662062C/en not_active Expired - Fee Related
-
2009
- 2009-01-26 IL IL196736A patent/IL196736A/en active IP Right Grant
- 2009-01-29 CR CR10591A patent/CR10591A/es not_active Application Discontinuation
- 2009-01-29 NO NO20090451A patent/NO20090451L/no not_active Application Discontinuation
- 2009-01-30 CO CO09008773A patent/CO6251278A2/es not_active Application Discontinuation
- 2009-02-25 MA MA31660A patent/MA30660B1/fr unknown
- 2009-10-09 US US12/576,266 patent/US20100035817A1/en not_active Abandoned
-
2010
- 2010-04-27 US US12/767,829 patent/US20100210547A1/en not_active Abandoned
-
2012
- 2012-08-21 US US13/590,549 patent/US8476232B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8476232B2 (en) | 2013-07-02 |
CN101511390A (zh) | 2009-08-19 |
AU2007291502A1 (en) | 2008-03-06 |
EP2059261A1 (en) | 2009-05-20 |
MA30660B1 (fr) | 2009-08-03 |
US20130065831A1 (en) | 2013-03-14 |
CN101511390B (zh) | 2013-04-24 |
PE20080912A1 (es) | 2008-07-19 |
EP2059261B1 (en) | 2012-10-24 |
CO6251278A2 (es) | 2011-02-21 |
CL2007002502A1 (es) | 2008-05-30 |
WO2008025528A1 (en) | 2008-03-06 |
IL196736A (en) | 2013-10-31 |
AU2007291502B2 (en) | 2012-05-31 |
US20100035817A1 (en) | 2010-02-11 |
KR20090046875A (ko) | 2009-05-11 |
AR062575A1 (es) | 2008-11-19 |
RU2009106118A (ru) | 2010-10-10 |
CA2662062C (en) | 2015-06-23 |
US20080119409A1 (en) | 2008-05-22 |
TW200819468A (en) | 2008-05-01 |
JP5184532B2 (ja) | 2013-04-17 |
MX2009002011A (es) | 2009-03-05 |
KR101106931B1 (ko) | 2012-01-25 |
US7625996B2 (en) | 2009-12-01 |
US20100210547A1 (en) | 2010-08-19 |
CA2662062A1 (en) | 2008-03-06 |
ES2397660T3 (es) | 2013-03-08 |
BRPI0715943A2 (pt) | 2013-07-30 |
NO20090451L (no) | 2009-02-26 |
JP2010501192A (ja) | 2010-01-21 |
IL196736A0 (en) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10591A (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol | |
ES2600879T3 (es) | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas | |
ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
RU2017123283A (ru) | Партнеры по слиянию для получения пептидов | |
PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
JP2017536835A5 (es) | ||
UY31123A1 (es) | Proteinas de fusion natriureticas | |
AR056138A1 (es) | Procedimiento para la expresion recombinante de un polipeptido | |
ECSP064643A (es) | Proteinas de fusion de glp-1 | |
PE20140867A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso | |
ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
AR093626A1 (es) | Proteinas de fusion de enzima lisosomal y usos de las mismas | |
DK1874932T3 (da) | Produktion af rekombinante proteiner ved autoproteolytisk spaltning af et fusionsprotein | |
AR065074A1 (es) | Peptidos de senalizacion | |
AR071969A1 (es) | Proteasa especifica de prolina identificada en el hongo penicillium chrysogenum | |
ES2531402T3 (es) | Colagenasa de fusión a la que se une una marca de afinidad, y método para producir la misma | |
WO2013091661A3 (en) | Proteolytic resistant protein affinity tag | |
ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
ES2545614T3 (es) | Proteínas truncadas con nudo de cistina | |
PE20020857A1 (es) | Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras | |
DK2059525T3 (da) | Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |